A detailed history of Caption Management, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Caption Management, LLC holds 590,000 shares of APLS stock, worth $16.6 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
590,000
Previous 1,004,700 41.28%
Holding current value
$16.6 Million
Previous $38.5 Million 55.85%
% of portfolio
0.3%
Previous 0.63%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$28.84 - $41.15 $6.17 Million - $8.81 Million
-213,994 Reduced 49.77%
216,006 $6.23 Million
Q2 2024

Aug 14, 2024

BUY
$38.07 - $59.71 $15.2 Million - $23.8 Million
399,000 Added 1287.1%
430,000 $16.5 Million
Q1 2024

May 15, 2024

SELL
$55.39 - $72.47 $20.1 Million - $26.2 Million
-362,031 Reduced 92.11%
31,000 $1.82 Million
Q4 2023

Feb 14, 2024

BUY
$37.14 - $64.82 $4.45 Million - $7.76 Million
119,781 Added 43.84%
393,031 $23.5 Million
Q3 2023

Nov 14, 2023

BUY
$23.65 - $89.22 $6.46 Million - $24.4 Million
273,026 Added 121886.61%
273,250 $10.4 Million
Q2 2023

Aug 14, 2023

BUY
$76.68 - $93.31 $17,176 - $20,901
224 New
224 $20,000
Q4 2022

Feb 14, 2023

BUY
$43.24 - $61.04 $735,080 - $1.04 Million
17,000 New
17,000 $879,000
Q4 2021

Feb 11, 2022

BUY
$30.74 - $49.16 $6.1 Million - $9.76 Million
198,557 Added 925.98%
220,000 $10.4 Million
Q3 2021

Nov 12, 2021

SELL
$31.4 - $69.84 $1.54 Million - $3.43 Million
-49,057 Reduced 69.58%
21,443 $707,000
Q2 2021

Aug 16, 2021

BUY
$40.9 - $64.9 $2.68 Million - $4.25 Million
65,500 Added 1310.0%
70,500 $4.46 Million
Q1 2021

May 17, 2021

BUY
$40.8 - $57.39 $204,000 - $286,950
5,000 New
5,000 $214,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.08B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.